Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of neoadjuvant pemetrexed + cisplatin chemoradiotherapy for resectable stage IIIA-N2 non-squamous NSCLC
ChiCTR-ONC-12002996Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and cisplatin in non-small cell lung cancer (NSCLC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-free survival. Started Feb 2013; status: recruiting.
02
Drugs
pemetrexedcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-ONC-12002996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-12002996.